| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
James Emmett Young last filed a Form 4 in May 2025, as Chief Financial Officer at TLSI. James Emmett Young's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 49,663 shares of TLSI. Net of sales, the TLSI filings show accumulation of 30,000 shares.
James Emmett Young has 4 Form 4 filings on record from January 2025 to May 2025, all as Chief Financial Officer at TriSalus Life Sciences (TLSI), 2025.
The 6 reported transactions were 3 stock awards, 2 open-market purchases and 1 option or other derivative award.
Counted by filing, the open-market trades come to 2 purchases worth about $164K and no sales.
The largest open-market purchase was 24,000 shares of TLSI at an average $5.40 on January 27, 2025, about $130K. Twelve months later TLSI was down 2%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.